Report Description

Global Botanical & Plant Derived Drug Market is estimated to have 6.4% of CAGR during the forecast period 2016-2023. Botanical drugs are derived from medicinal plants. They are used for diagnosis, treatment and mitigation of diseases in humans. The recent trend driving the botanical and plant derived drug market is the increasing use of herbal medicines. Herbal medicines are used by 70%-80% of the world population especially in developing nations for primary health care due to few side effects, low cost and its easy avaibility. According to the World Health Organization (WHO), the use of herbal remedies across the world increased 2-3 times as compared to the use of traditional drugs in 2015. The factors contributing to the growth of global botanical & plant derived drug market are as follows:

Increase in the number of chronic diseases
Technological advancement in production procedure
Cost effectiveness
Increase in use of plant derived drugs

The key factor driving the growth of global botanical & plant derived drug market is the increasing number of chronic diseases which has led to the acceptance of herbal medicines. . According to World Health Organization (WHO), non-communicable chronic diseases (NCDs) were responsible for over 62% of the total mortality in 2016 with approximately 60 million deaths. Over 80% of deaths in developing nations (specifically China and India) are due to NCDs such as diabetes, cancer, obesity and cardiovascular diseases. Global burden of NCDs in 2016 was 50% and is expected to increase up to 57% by 2020. . Rate of NCDs are higher among adults aged 55 years and above. However, an increase of 15% in NCDs can be seen in the younger population too. WHO estimates that the number of people affected with diabetes will reach up to 235 million by 2020 as compared to 186 million in 2015. In next five years, prevalence of obesity in Africa, Latin America and Asia Pacific is expected to increase by 3%. Diabetes, cancer and cardiovascular diseases are the prime causes of deaths in India and China. The number of people suffering with cancer in Asia Pacific is expected to reach over 15 million by 2019. In Asia Pacific lung cancer, prostate cancer, and breast cancer are among the most common forms of cancer. In 2015, the total burden of heart disease and stroke in US accounted for over $320 billion. According to National Cancer Institute, the number of people suffering from cancer is expected to increase up to 19 million by 2024, from 15 million in 2015. Breast cancer, lung and bronchus cancer are amongst the most common forms of cancer in North America. NCDs accounted for 86% of the deaths in Europe in 2015. However, factors like stringent government laws & regulations, low acceptance rate for lethal diseases, lack of awareness about botanical drugs, and availability of substitutes are restraining the growth of global botanical & plant derived drug market for the forecast period. However the enhanced application and increasing approval by FDA is creating future opportunities for the market. Over the years, treatment of cancer with plants like Withania somnifera, Tinospora codifolia, and Asparagus racemases has increased. They are developed as a supportive treatment with chemotherapy. Drugs from other plants like Huang Qi, Podophyllum platinum, Saguinaria canadenesis, and Ruscus aculeatus are still in its development stage for cancer treatment. Herbs like Cynara scolymus, Allium Sativum, and Ginkgo bilboa have found to be useful in treatment of coronary heart diseases which is creating an opportunity for global botanical & plant derived drug market. Major challenges faced by this market are lack of awareness about botanical drugs and availability of alternatives.

Source: OBRC Analysis.

The global botanical and plant derived drugs market is segmented into drug type and application.

Drug type is further segmented into:

Steroids
Phenols
Terpenes
Glycosides

Application is further segmented into:

Hormonal diseases
Respiratory and oncology diseases
Infectious diseases
Cardiovascular and metabolic diseases
Pain & CNS disorder

The revenue for the above application segments is specific to the botanical and plant derived drug market. However, the total revenue of these applications in general has been excluded from the scope of the report. Also, the total market revenue has been calculated by summing up drug type segment.

Geographically, the global botanical and plant derived drug market is segmented into:

North America (U.S. & Canada)
Asia Pacific (China, India, Japan, RoAPAC)
Europe (UK, France, Germany, RoE)
Rest of World

North America had the largest market share in2016, due to the increasing awareness of botanical drugs and plant derived drugs, sound regulatory environment and rising prevalence of diseases. Asia Pacific is expected to have the highest growth rate for the forecast period due to increasing healthcare expenditure and increasing prevalence of chronic diseases. India, China, and Japan are the leading markets for the forecast period.

Global botanical and plant derived drug market is segmented into drug type and applications. By drug type the market is further bifurcated into steroids, phenols, terpenes, and glycosides. Phenols dominates drug type segment in terms of revenue in 2016. One the basis of application, the market is further classified into hormone disease, infectious disease, pain & CNS disorder, cardiovascular & metabolic disease and respiratory & oncology disease. Cardiovascular & metabolic disease is the largest application of botanical & plant derived drug market in 2016.

The major market players of the global botanical & plant derived drug market are:

ABBOTT LABORATORIES
BAYER HEALTHCARE LTD
BIONOVA INC
BRISTOL MEYERS LTD.,
ELI LILLY LTD.,
OTHERS

Detailed analysis of these companies provided in this report comprises of overview, scot analysis, product portfolio, strategic initiative and strategic analysis.

These companies use various strategies such as mergers & acquisitions, collaboration, partnership and product launching. Example: In April 2016, Abbott laboratories acquired St. Jude Medical. This created a huge opportunity for Abbott to become a premier medical device leader along with high-growing cardiovascular markets which included structural heart, atrial fibrillation and heart failure. It strengthened Abbott’s long term growth. This acquisition helped to improve Abbott’s capabilities and overall global scale by diversifying its portfolio and revenue sources. Thus acquisition improved it strategic and competitive positions as it provided well-managed diversity to deliver reliable, sustainable growth.

Why to buy the report:

This report will:

Provide you the business strategies adopted by market player such as acquisition as in April 2016 Abbott laboratories acquired St. Jude Medical.
Provide in detail the different segments such as drug type and application which affect the global botanical and plant derived drug market.
Provide you the patent analysis of global botanical and plant derived drug market.
Identify and understand the strengths, opportunities, challenges and threat of global botanical & plant derived DRUG MARKET.
Provide revenues of major players of the market such as Abbott Laboratories Ltd., Bayer Healthcare Ltd., Bionova Inc., Bristol Meyers Ltd., Eli Lilly Ltd., and GSK Ltd.
Provide you the various regulatory policies which affect the global botanical and plant derived drug market.

How we are different from others:

At Occams we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentations. Our report on global botanical and plant derived drug market offers the longest chain of market segmentation covering major segmentation based on type of drugs and applications.The report tracks the major market trends in the globalbotanical and plant derived DRUG MARKET such as rising demand of herbal medicines in health care sector and technological advancement in drug production. For each market segments covered in globalbotanical and plant derived DRUG MARKET report, we provide opportunity matrix, and DROC analysis, that enable the clear growth assessment across each market segment. The report discusses competitive landscape of the plant derived drug market, with giving extensive strategy analysis of more than 15 companies. Moreover, the report discusses various models such as 360 degree analysis, See Saw analysis, and Porter five force model and so on. For the high level analysis in the report we provide a comparative analysis of historic and current year data.

Key findings of the global botanical and plant derived drug market.

North America had the largest revenue share in 2016.
Phenols dominates drug type segment in terms of revenue in 2016
Acquisition is the key strategy adopted by the various market players of global botanical and plant derived drug market.
Cardiovascular & metabolic disease is the largest application of botanical & plant derived drug market.

Table of Content

1. INTRODUCTION

1.1. EXECUTIVE SUMMARY

1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

2.1. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET: EVOLUTION & TRANSITION

2.2. MARKET DEFINITION & SCOPE

2.3. INDUSTRY STRUCTURE

2.4. REGULATORY FRAMEWORK

2.5. TOTAL MARKET ANALYSIS

2.5.1. TOP 5 FINDINGS

2.5.2. TOP 5 OPPORTUNITY MARKETS

2.5.3. TOP 5 COMPANIES

2.5.4. TOP 3 COMPETITIVE STRATEGIES

2.6. ESTIMATION ANALYSIS

2.7. STRATEGIC ANALYSIS

2.7.1. INVESTMENT VS. ADOPTION MODEL

2.7.2. 360 DEGREE INDUSTRY ANALYSIS

2.7.3. PORTERS 5 FORCE MODEL

2.7.4. SEE-SAW ANALYSIS

2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA

2.8. COMPETITIVE ANALYSIS

2.8.1. KEY STRATEGIES & ANALYSIS

2.8.2. MARKET SHARE ANALYSIS&TOP COMPANY ANALYSIS

2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS

2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS

2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS

2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

3.1. MARKET DRIVERS

3.1.1. INCREASING PREVALENCE OF CHRONIC DISEASES

3.1.2. TECHNOLOGICAL ADVANCEMENT IN PRODUCTION PROCEDURE

3.1.3. COMPARATIVELY LOW PRICE

3.1.4. INCREASE IN USE OF PLANT DERIVED DRUGS

3.2. MARKET RESTRAINTS

3.2.1. STRINGENT GOVERNMENT LAWS & REGULATIONS

3.2.2. LOW ACCEPTANCE RATE FOR LETHAL DISEASES

3.3. MARKET OPPORTUNITIES

3.3.1. ENHANCED APPLICATIONS

3.3.2. INCREASING APPROVAL BY FDA

3.4. MARKET CHALLENGES

3.4.1. LACK OF AWARENESS ABOUT BOTANICAL DRUGS

3.4.2. AVAILABILITY OF ALTERNATIVE SUBSTITUTES

4. MARKET SEGMENTATION

4.1. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET BY DRUG TYPE

4.1.1. MARKET DEFINITION AND SCOPE

4.1.2. DECISION SUPPORT

4.1.3. DATABASE & ESTIMATION METHODOLOGY

4.1.4. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

4.1.5. OPPORTUNITY MATRIX

4.1.6. MARKET SEGMENTATION

4.1.6.1. GLOBAL STEROIDS MARKET

4.1.6.1.1. APPLICATION

4.1.6.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.6.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.6.1.4. TOP PLAYERS & KEY PRODUCTS

4.1.6.1.5. KEY CONCLUSIONS

4.1.6.2. GLOBAL PHENOLS MARKET

4.1.6.2.1. APPLICATION

4.1.6.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.6.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.6.2.4. TOP PLAYERS & KEY PRODUCTS

4.1.6.2.5. KEY CONCLUSIONS

4.1.6.3. GLOBAL TERPENES MARKET

4.1.6.3.1. APPLICATION

4.1.6.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.6.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.6.3.4. TOP PLAYERS & KEY PRODUCTS

4.1.6.3.5. KEY CONCLUSIONS

4.1.6.4. GLOBAL GLYCOSIDES MARKET

4.1.6.4.1. APPLICATION

4.1.6.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.6.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.6.4.4. TOP PLAYERS & KEY PRODUCTS

4.1.6.4.5. KEY CONCLUSIONS

4.1.6.5. GLOBAL OTHERS MARKET

4.1.6.5.1. APPLICATION

4.1.6.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.6.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.6.5.4. TOP PLAYERS & KEY PRODUCTS

4.1.6.5.5. KEY CONCLUSIONS

4.2. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET BY APPLICATION

4.2.1. MARKET DEFINITION AND SCOPE

4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

4.2.4. OPPORTUNITY MATRIX

4.2.5. MARKET SEGMENTATION

4.2.5.1. GLOBAL HORMONE DISEASES MARKET

4.2.5.1.1. APPLICATION

4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.2.5.1.4. TOP PLAYERS & KEY PRODUCTS

4.2.5.1.5. KEY CONCLUSIONS

4.2.5.2. GLOBAL RESPIRATORY & ONCOLOGY DISEASE MARKET

4.2.5.2.1. APPLICATION

4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.2.5.2.4. TOP PLAYERS & KEY PRODUCTS

4.2.5.2.5. KEY CONCLUSIONS

4.2.5.3. GLOBAL INFECTIOUS DISEASE MARKET

4.2.5.3.1. APPLICATION

4.2.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.2.5.3.4. TOP PLAYERS & KEY PRODUCTS

4.2.5.3.5. KEY CONCLUSIONS

4.2.5.4. GLOBALCARDIOVASCULAR & METABOLIC DISEASE MARKET

4.2.5.4.1. APPLICATION

4.2.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.2.5.4.4. TOP PLAYERS & KEY PRODUCTS

4.2.5.4.5. KEY CONCLUSIONS

4.2.5.5. GLOBAL PAIN & CNS DISORDER MARKET

4.2.5.5.1. APPLICATION

4.2.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.2.5.5.4. TOP PLAYERS & KEY PRODUCTS

4.2.5.5.5. KEY CONCLUSIONS

5. COMPETITIVE LANDSCAPE

5.1. KEY STRATEGIES

5.1.1. LIST OF MERGERS &ACQUISITION

5.1.2. LIST OF JOINT VENTURES

5.1.3. LIST OF PRODUCT LAUNCHES

5.1.4. LIST OF PARTNERSHIPS

6. GEOGRAPHICAL ANALYSIS

6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

6.3. OPPORTUNITY MATRIX

6.4. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET BY REGION 2014-2023 ($ MILLION)

6.4.1. NORTH AMERICA

6.4.1.1. INDUSTRIAL END-USER ANALYSIS 2014-2023 ($ MILLION)

6.4.1.2. TOP COUNTRY ANALYSIS

6.4.1.2.1. U.S.

6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS

6.4.1.2.1.3. KEY CONCLUSIONS

6.4.1.2.2. CANADA

6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS

6.4.1.2.2.3. KEY CONCLUSIONS

6.4.2. EUROPE

6.4.2.1. INDUSTRY END-USER ANALYSIS 2014-2023 ($ MILLION)

6.4.2.2. TOP COUNTRY ANALYSIS

6.4.2.2.1. UK

6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS

6.4.2.2.1.3. KEY CONCLUSIONS

6.4.2.2.2. FRANCE

6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS

6.4.2.2.2.3. KEY CONCLUSIONS

6.4.2.2.3. GERMANY

6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS

6.4.2.2.3.3. KEY CONCLUSIONS

6.4.2.2.4. SPAIN

6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS

6.4.2.2.4.3. KEY CONCLUSIONS

6.4.2.2.5. REST OF EUROPE

6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS

6.4.2.2.5.3. KEY CONCLUSIONS

6.4.3. ASIA PACIFIC

6.4.3.1. INDUSTRY END-USER ANALYSIS 2014-2023 ($ MILLION)

6.4.3.2. TOP COUNTRY ANALYSIS

6.4.3.2.1. CHINA

6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS

6.4.3.2.1.3. KEY CONCLUSIONS

6.4.3.2.2. INDIA

6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS

6.4.3.2.2.3. KEY CONCLUSIONS

6.4.3.2.3. JAPAN

6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS

6.4.3.2.3.3. KEY CONCLUSIONS

6.4.3.2.4. AUSTRALIA

6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS

6.4.3.2.4.3. KEY CONCLUSIONS

6.4.3.2.5. REST OF ASIA PACIFIC

6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS

6.4.3.2.5.3. KEY CONCLUSIONS

6.4.4. ROW

6.4.4.1. INDUSTRY END-USER ANALYSIS 2014-2023 ($ MILLION)

6.4.4.2. TOP COUNTRY ANALYSIS

6.4.4.2.1. LATIN AMERICA

6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS

6.4.4.2.1.3. KEY CONCLUSIONS

6.4.4.2.2. MIDDLE EAST & AFRICA

6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS

6.4.4.2.2.3. KEY CONCLUSIONS

7. COMPANY PROFILES

7.1. ABBOTT LABORATORIES

7.1.1. OVERVIEW

7.1.2. PRODUCT PORTFOLIO

7.1.3. KEY INNOVATION SECTOR

7.1.4. STRATEGIC INITIATIVES

7.1.5. SCOT ANALYSIS

7.1.6. STRATEGIC ANALYSIS

7.2. BAYER HEALTHCARE

7.2.1. OVERVIEW

7.2.2. PRODUCT PORTFOLIO

7.2.3. KEY INNOVATION SECTOR

7.2.4. STRATEGIC INITIATIVES

7.2.5. SCOT ANALYSIS

7.2.6. STRATEGIC ANALYSIS

7.3. BIONOVA

7.3.1. OVERVIEW

7.3.2. PRODUCT PORTFOLIO

7.3.3. KEY INNOVATION SECTOR

7.3.4. STRATEGIC INITIATIVES

7.3.5. SCOT ANALYSIS

7.3.6. STRATEGIC ANALYSIS

7.4. BRISTOL MEYERS

7.4.1. OVERVIEW

7.4.2. PRODUCT PORTFOLIO

7.4.3. KEY INNOVATION SECTOR

7.4.4. STRATEGIC INITIATIVES

7.4.5. SCOT ANALYSIS

7.4.6. STRATEGIC ANALYSIS

7.5. ELI LILLY

7.5.1. OVERVIEW

7.5.2. PRODUCT PORTFOLIO

7.5.3. KEY INNOVATION SECTOR

7.5.4. STRATEGIC INITIATIVES

7.5.5. SCOT ANALYSIS

7.5.6. STRATEGIC ANALYSIS

7.6. GSK LTD

7.6.1. OVERVIEW

7.6.2. PRODUCT PORTFOLIO

7.6.3. KEY INNOVATION SECTOR

7.6.4. STRATEGIC INITIATIVES

7.6.5. SCOT ANALYSIS

7.6.6. STRATEGIC ANALYSIS

7.7. JHONSON & JHONSON

7.7.1. OVERVIEW

7.7.2. PRODUCT PORTFOLIO

7.7.3. KEY INNOVATION SECTOR

7.7.4. STRATEGIC INITIATIVES

7.7.5. SCOT ANALYSIS

7.7.6. STRATEGIC ANALYSIS

7.8. LUPIN LTD

7.8.1. OVERVIEW

7.8.2. PRODUCT PORTFOLIO

7.8.3. KEY INNOVATION SECTOR

7.8.4. STRATEGIC INITIATIVES

7.8.5. SCOT ANALYSIS

7.8.6. STRATEGIC ANALYSIS

7.9. MEDIGENE

7.9.1. OVERVIEW

7.9.2. PRODUCT PORTFOLIO

7.9.3. KEY INNOVATION SECTOR

7.9.4. STRATEGIC INITIATIVES

7.9.5. SCOT ANALYSIS

7.9.6. STRATEGIC ANALYSIS

7.10. NOVARTIS INTERNATIONAL

7.10.1. OVERVIEW

7.10.2. PRODUCT PORTFOLIO

7.10.3. KEY INNOVATION SECTOR

7.10.4. STRATEGIC INITIATIVES

7.10.5. SCOT ANALYSIS

7.10.6. STRATEGIC ANALYSIS

7.11. PFIZER

7.11.1. OVERVIEW

7.11.2. PRODUCT PORTFOLIO

7.11.3. KEY INNOVATION SECTOR

7.11.4. STRATEGIC INITIATIVES

7.11.5. SCOT ANALYSIS

7.11.6. STRATEGIC ANALYSIS

7.12. RANBAXY LABS

7.12.1. OVERVIEW

7.12.2. PRODUCT PORTFOLIO

7.12.3. KEY INNOVATION SECTOR

7.12.4. STRATEGIC INITIATIVES

7.12.5. SCOT ANALYSIS

7.12.6. STRATEGIC ANALYSIS

7.13. GLENMARK PHARMACEUTICALS LTD

7.13.1. OVERVIEW

7.13.2. PRODUCT PORTFOLIO

7.13.3. KEY INNOVATION SECTOR

7.13.4. STRATEGIC INITIATIVES

7.13.5. SCOT ANALYSIS

7.13.6. STRATEGIC ANALYSIS

7.14. TASLY PHARMACEUTICALS INC

7.14.1. OVERVIEW

7.14.2. PRODUCT PORTFOLIO

7.14.3. KEY INNOVATION SECTOR

7.14.4. STRATEGIC INITIATIVES

7.14.5. SCOT ANALYSIS

7.14.6. STRATEGIC ANALYSIS

7.15. PIRAMAL PHYTOCARE LTD

7.15.1. OVERVIEW

7.15.2. PRODUCT PORTFOLIO

7.15.3. KEY INNOVATION SECTOR

7.15.4. STRATEGIC INITIATIVES

7.15.5. SCOT ANALYSIS

7.15.6. STRATEGIC ANALYSIS

LIST OF TABLES

1. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET BY DRUG TYPE 2014-2023 ($ MILLION)

2. GLOBAL STEROID MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

3. GLOBAL PHENOL MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

4. GLOBAL TERPENES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

5. GLOBAL GLYCOSIDES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

6. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET BY APPLICATION 2014-2023 ($ MILLION)

7. GLOBAL HORMONE DISEASE APPLICATION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

8. GLOBAL PAIN & CNS DISORDER APPLICATION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

9. GLOBAL RESPIRATORY & ONCOLOGY DISEASE APPLICATION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

10. GLOBAL INFECTIOUS DISEASE APPLICATION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

11. GLOBAL DRUG IN CARDIOVASCULAR & METABOLIC DISEASE APPLICATION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

12. NORTH AMERICA BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

13. EUROPE BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

14. ASIA PACIFIC BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

15. REST OF THE WORLD BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

LIST OF FIGURES

1. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET BY STEROID 2014-2023 ($ MILLION)

2. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET BY PHENOL 2014-2023 ($ MILLION)

3. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET BY TERPENES 2014-2023 ($ MILLION)

4. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET BY GLYCOSIDES 2014-2023 ($ MILLION)

5. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET IN HORMONE DISEASE 2014-2023 ($ MILLION)

6. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET IN PAIN & CNS DISORDER 2014-2023 ($ MILLION)

7. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET IN RESPIRATORY & ONCOLOGY 2014-2023 ($ MILLION)

8. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET IN INFECTIOUS DISEASE 2014-2023 ($ MILLION)

9. GLOBAL BOTANICAL & PLANT DERIVED DRUG MARKET IN CARDIOVASCULAR & METABOLIC DISEASE 2014-2023 ($ MILLION)

10. UNITED STATES (U.S.) BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

11. CANADA BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

12. UNITED KINGDOM (UK) BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

13. FRANCE BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

14. GERMANY BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

15. SPAIN BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

16. ROE BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

17. INDIA BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

18. CHINA BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

19. JAPAN BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

20. AUSTRALIABOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

21. ROAPAC BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

22. LATIN AMERICA BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

23. MENA BOTANICAL & PLANT DERIVED DRUG MARKET 2014-2023 ($ MILLION)

Enquiry before Buying

FAQ

How can I purchase a report?

We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.

How safe is to use my credit card? Is my information secure?

We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.

Can I get a discount?

We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.

I want to buy only a chapter. I don't need complete report.

Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.

Can I get reports on my desired topic specially which is not available in your current portfolio?

Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.

When do I get access to the report(s) that I have purchased?

We will email you your purchased report right after we receive your payment through any of the payment options.

Will I receive any invoice for my purchase?

Yes we will email you invoice/payment confirmation with the order details once we receive your payment.

In what format will the reports be available in?

All the reports will be available in PDF format for download.

Request for Sample

Name*

Email Id*

Phone

Designation

Company Name

Country

Report Title

Type Characters*

Login

Forgot Password

Thank you for your request!

Thank you for downloading..!

Global Botanical & Plant Derived Drug Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 – 2023

FAQ

Request for Sample

UPCOMING REPORTS

NAVIGATION LINK

OUR SERVICES

CONNECT WITH US